サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1794662

プリオン病治療の世界市場

Prion Disease Treatment

出版日
ページ情報
英文 268 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.16円
プリオン病治療の世界市場
出版日: 2025年08月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 268 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

プリオン病治療の世界市場は2030年までに57億米ドルに到達

2024年に48億米ドルと推定されるプリオン病治療の世界市場は、2024年から2030年にかけてCAGR 2.9%で成長し、2030年には57億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるヒト治療は、CAGR 2.2％を記録し、分析期間終了時には34億米ドルに達すると予測されます。動物治療分野の成長率は、分析期間中CAGR 4.0%と推定されます。

米国市場は13億米ドルと推定、中国はCAGR 5.4％で成長予測

米国のプリオン病治療市場は2024年に13億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに11億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは5.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.2％と2.2％と予測されています。欧州では、ドイツがCAGR 1.6%で成長すると予測されています。

世界のプリオン病治療市場- 主要動向と促進要因のまとめ

プリオン病治療が科学的・臨床的に再注目されている理由とは？

伝達性海綿状脳症（TSE）としても知られるプリオン病は、稀ではあるが致死的な神経変性疾患であり、プリオンタンパク質のミスフォールディングを特徴とし、脳障害と急速な認知機能低下をもたらします。その有病率の低さにもかかわらず、クロイツフェルト・ヤコブ病（CJD）、変異型CJD（vCJD）、致死性家族性不眠症（FFI）、クル病などのプリオン病は、研究者からも規制当局からもますます注目を集めています。根治的な治療法がないこと、また一般的に疾患の進行が速いことから、診断法、治療薬、支持療法戦略における早急な技術革新が必要とされています。

最近の分子生物学とプリオン蛋白化学の進歩は、創薬プログラムを活性化しています。研究は、正常なプリオンタンパク質（PrP^C）から病因型（PrP^Sc）への変換を阻止できる低分子阻害剤、抗プリオン抗体、RNA標的療法に集中しています。さらに、希少疾患イニシアチブからの資金提供の増加や、学界、政府機関、バイオテクノロジー企業間の協力的な取り組みにより、前臨床試験や初期段階の臨床試験が加速しています。ヒト化マウスモデル、PMCA（protein misfolding cyclic amplification）技術、RT-QuICアッセイの出現は、プリオン研究における標的の検証と治療スクリーニングをさらに強化しています。

開発パイプラインではどのような治療戦略や調査方法が検討されているか？

プリオン病治療状況は、対症療法と実験的な疾患修飾療法に大きく二分されます。現在の標準治療は、症状を緩和するための支持的介入-抗痙攣薬、抗うつ薬、筋弛緩薬など-に依存しているが、これらは根本的なタンパク質のミスフォールディング病態には対処していないです。実験的治療では、プリオンの複製や凝集を阻害するポリアニオン性化合物（ペントサン・ポリサルフェートなど）、抗プリオンモノクローナル抗体、siRNA分子などのアプローチを用いて、分子レベルで病気を標的としています。

低分子のアプローチでは、プリオンタンパク質に結合し、その本来のコンフォメーションを安定化させる化合物や、PrP^Sc凝集体を破壊する化合物が研究されています。さらに、薬剤の再利用の努力により、キナクリン、ドキシサイクリン、フルピルチンなどの候補が同定されているが、臨床成績はまだまちまちです。抗PrP抗体を用いた受動的免疫療法を含む免疫療法戦略は動物モデルで有望視されているが、血液脳関門を通過するという課題に直面しています。PRNP遺伝子のCRISPRを介したサイレンシングなどの遺伝子治療アプローチが前臨床レベルで検討されており、高リスク者や家族性キャリアにおけるプリオン合成を減少させる長期的な潜在的経路を提供しています。

市場開拓を支える診断、サーベイランス、規制の枠組みは？

プリオン病は臨床症状が多様であり、疾患の経過が速いため、早期かつ正確な診断が依然として重要な課題となっています。しかし、分子診断における技術革新は、検出の窓を狭めています。RT-QuICなどの技術により、脳脊髄液（CSF）や鼻腔ブラッシング液中の微量のPrP^Scの増幅と検出が可能になり、以前よりも高い特異性と感度で死前診断ができるようになりました。これらの進歩は、臨床試験のための患者層別化に役立ち、欧州、北米、アジア太平洋のサーベイランスプログラムに組み込まれています。

米国FDAやEMAなどの規制機関は、希少疾病用医薬品の指定、迅速審査、臨床試験への助成金支援を通じて、希少疾病治療開発を促進しています。英国や日本は、疫学データを収集し、異所性感染や人獣共通感染症をスクリーニングするために、TSEの基準研究所やモニタリングセンターを設立しています。EuroCJDや米国国立プリオン病病理学サーベイランスセンターのような各国のサーベイランス・ネットワーク間の世界の連携は、データ共有を合理化し、多施設共同試験を促進しています。このような構造的な改善は、これまでこの領域の臨床研究を妨げてきた患者数の少なさや診断の複雑さを克服するために不可欠です。

世界のプリオン病治療市場の成長を促進する要因は？

世界のプリオン病治療市場の成長は、アンメットメディカルニーズ、トランスレーショナルリサーチの増加、希少な神経変性疾患に対する規制上のインセンティブが原動力となっています。人口動態の高齢化により神経変性疾患の発生が加速する中、散発性CJDや家族性CJDのような希少変異型に対する認識と診断の高まりが予想されます。さらに、人獣共通感染症である牛海綿状脳症（BSE）や子牛の慢性消耗性疾患（CWD）などのプリオン病が再び台頭してきており、予防的・治療的ソリューションの開発に対する関心が高まっています。

NIHのBRAIN InitiativeやHorizon Europeの希少疾患プラットフォームなどのイニシアチブを含め、神経科学の研究開発への投資が増加しており、初期段階のイノベーションパイプラインが強化されています。製薬会社やバイオテクノロジー企業は、市場独占権やプレミアム価格設定が可能な、ニッチだがニーズの高い市場をターゲットとするようになっています。診断能力の向上、遺伝子スクリーニングの増加、精密医療の台頭は、患者の特定を改善し、より的を絞った介入を可能にしています。神経変性疾患という最も困難なカテゴリーのひとつに対して、前臨床段階での有望性を実行可能な治療法へと転換させるには、学術、規制、商業の各分野の努力の継続的な収束が不可欠です。

セグメント

治療薬（ヒト治療薬、動物治療薬）;医薬品（抗うつ薬、抗精神病薬）

調査対象企業の例

  • Abbott Laboratories
  • Alector, Inc.
  • Alnylam Pharmaceuticals
  • Amgen Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • CureVac AG
  • Eli Lilly and Company
  • Genentech（Roche Group）
  • Ionis Pharmaceuticals, Inc.
  • Merck KGaA
  • Neurotech Pharmaceuticals
  • Novartis AG
  • Orphazyme A/S
  • Prothena Biosciences, Inc.
  • Sage Therapeutics
  • Sangamo Therapeutics, Inc.
  • Teva Pharmaceuticals
  • Tetra Discovery Partners
  • Wave Life Sciences

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37824

Global Prion Disease Treatment Market to Reach US$5.7 Billion by 2030

The global market for Prion Disease Treatment estimated at US$4.8 Billion in the year 2024, is expected to reach US$5.7 Billion by 2030, growing at a CAGR of 2.9% over the analysis period 2024-2030. Human Treatment, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$3.4 Billion by the end of the analysis period. Growth in the Animal Treatment segment is estimated at 4.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 5.4% CAGR

The Prion Disease Treatment market in the U.S. is estimated at US$1.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 5.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Prion Disease Treatment Market - Key Trends & Drivers Summarized

Why Is the Prion Disease Treatment Landscape Gaining Renewed Scientific and Clinical Focus?

Prion diseases, also known as transmissible spongiform encephalopathies (TSEs), are rare but fatal neurodegenerative disorders characterized by the misfolding of prion proteins, leading to brain damage and rapid cognitive decline. Despite their low prevalence, prion diseases such as Creutzfeldt-Jakob Disease (CJD), variant CJD (vCJD), Fatal Familial Insomnia (FFI), and Kuru have garnered increasing attention from both researchers and regulatory agencies. The lack of curative therapies and the typically rapid disease progression necessitate urgent innovation in diagnostics, therapeutic agents, and supportive care strategies.

Recent advances in molecular biology and prion protein chemistry have revitalized drug discovery programs. Investigations are focusing on small-molecule inhibitors, anti-prion antibodies, and RNA-targeted therapies that can prevent the conversion of normal prion protein (PrP^C) into its pathogenic form (PrP^Sc). Additionally, increased funding from rare disease initiatives and collaborative efforts between academia, government agencies, and biotech companies are accelerating preclinical and early-stage clinical studies. The emergence of humanized mouse models, protein misfolding cyclic amplification (PMCA) techniques, and RT-QuIC assays are further enhancing target validation and therapeutic screening in prion research.

What Treatment Strategies and Research Modalities Are Being Explored Across the Development Pipeline?

The prion disease treatment landscape is largely divided between symptomatic care and experimental disease-modifying therapies. Current standards of care rely on supportive interventions-such as anticonvulsants, antidepressants, and muscle relaxants-to alleviate symptoms, but these do not address the underlying protein misfolding pathology. Experimental treatments are targeting the disease at a molecular level, using approaches such as polyanionic compounds (e.g., pentosan polysulfate), anti-prion monoclonal antibodies, and siRNA molecules to block prion replication or aggregation.

Small-molecule approaches are investigating compounds that bind to prion protein and stabilize its native conformation or disrupt PrP^Sc aggregates. Additionally, drug repurposing efforts have identified candidates such as quinacrine, doxycycline, and flupirtine, although clinical results remain mixed. Immunotherapeutic strategies-including passive immunization using anti-PrP antibodies-have shown promise in animal models but face challenges in crossing the blood-brain barrier. Gene therapy approaches, such as CRISPR-mediated silencing of the PRNP gene, are being explored at the preclinical level, offering a long-term potential route to reduce prion synthesis in high-risk individuals or familial carriers.

How Are Diagnostics, Surveillance, and Regulatory Frameworks Supporting Market Development?

Early and accurate diagnosis remains a significant challenge due to the heterogeneous clinical presentation and rapid disease course of prion disorders. However, innovations in molecular diagnostics are narrowing the detection window. Techniques such as RT-QuIC allow for the amplification and detection of minute amounts of PrP^Sc in cerebrospinal fluid (CSF) and nasal brushings, enabling ante-mortem diagnosis with higher specificity and sensitivity than previously possible. These advances are aiding in patient stratification for clinical trials and are being incorporated into surveillance programs across Europe, North America, and Asia-Pacific.

Regulatory bodies such as the U.S. FDA and the EMA are facilitating rare disease treatment development through orphan drug designations, fast-track reviews, and grant support for clinical studies. The U.K. and Japan have also established TSE reference laboratories and monitoring centers to collect epidemiological data and screen for iatrogenic or zoonotic transmissions. Global collaboration among national surveillance networks-such as EuroCJD and the U.S. National Prion Disease Pathology Surveillance Center-is streamlining data sharing and facilitating multicenter trials. These structural improvements are critical for overcoming the small patient population and diagnostic complexity that have historically hindered clinical research in this domain.

What Factors Are Driving the Growth of the Global Prion Disease Treatment Market?

The growth in the global prion disease treatment market is driven by unmet medical need, increasing translational research, and regulatory incentives for rare neurodegenerative diseases. As demographic aging accelerates the incidence of neurodegenerative disorders, greater awareness and diagnosis of rare variants such as sporadic and familial CJD are expected. Additionally, the re-emergence of zoonotic prion diseases-such as Bovine Spongiform Encephalopathy (BSE) and Chronic Wasting Disease (CWD) in cervids-is renewing interest in the development of prophylactic and therapeutic solutions.

Growing investment in neuroscience R&D, including through initiatives like the NIH’s BRAIN Initiative and Horizon Europe’s rare disease platforms, is strengthening the early-stage innovation pipeline. Pharmaceutical and biotech companies are increasingly targeting niche but high-need markets where market exclusivity and premium pricing are attainable. Enhanced diagnostic capabilities, increased genetic screening, and the rise of precision medicine are improving patient identification and enabling more targeted interventions. Continued convergence of academic, regulatory, and commercial efforts will be critical in translating preclinical promise into viable therapies for one of the most challenging categories of neurodegenerative disease.

SCOPE OF STUDY:

The report analyzes the Prion Disease Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Human Treatment, Animal Treatment); Drug (Antidepressant Drugs, Antipsychotic Agents)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

  • Abbott Laboratories
  • Alector, Inc.
  • Alnylam Pharmaceuticals
  • Amgen Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • CureVac AG
  • Eli Lilly and Company
  • Genentech (Roche Group)
  • Ionis Pharmaceuticals, Inc.
  • Merck KGaA
  • Neurotech Pharmaceuticals
  • Novartis AG
  • Orphazyme A/S
  • Prothena Biosciences, Inc.
  • Sage Therapeutics
  • Sangamo Therapeutics, Inc.
  • Teva Pharmaceuticals
  • Tetra Discovery Partners
  • Wave Life Sciences

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Prion Disease Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness and Diagnostic Advancements Propel Demand for Prion Disease Therapeutics
    • Increased Government Funding for Rare Disease Research Expands Scope for Therapeutic Innovation
    • Lack of Effective Treatments Throws the Spotlight on Unmet Clinical Needs in Prion Disorders
    • OEM Collaborations With Academic Research Institutes Accelerate Preclinical Pipeline Development
    • Technological Advancements in Protein Misfolding Assays Enhance Early Diagnosis Capabilities
    • Growth in Companion Diagnostic Tools Strengthens Case for Targeted Therapeutic Development
    • Regulatory Incentives for Orphan Drug Designation Promote Investment in Novel Mechanisms
    • Increased Focus on Neurodegenerative Disease Pathways Fuels Interest in Prion Aggregation Inhibitors
    • Emergence of RNA-Based and Antibody Therapies Drives Hope for Disease-Modifying Interventions
    • Demand for Biomarker-Based Progression Monitoring Supports Clinical Trial Endpoint Validation
    • Expansion of Brain Bank and Tissue Research Infrastructure Enhances Pathology Understanding
    • Rising Incidence of iatrogenic and variant Creutzfeldt-Jakob Disease Creates Public Health Priority
    • Push for Animal Disease Surveillance and Zoonotic Risk Monitoring Strengthens Early Intervention Frameworks
    • Private-Public Research Collaborations Create Opportunities for Translational Funding Support
    • Adoption of AI in Disease Modeling and Drug Repurposing Promotes Rapid Screening of Candidates
    • Patient Advocacy and Support Networks Strengthen Awareness and Accelerate Trial Participation
    • Growth in Academic-Industry Licensing Deals for Prion-Targeted Technologies Fuels Innovation Pipelines
    • Data Sharing Consortia and Global Registries Promote Longitudinal Study of Disease Progression
    • Regulatory Harmonization Across US and EU Encourages Simultaneous Approval Pathways
    • Challenges in Blood and Surgical Transmission Risk Spur Development of Preventive Therapeutics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Prion Disease Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Prion Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Prion Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Prion Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Human Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Human Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Human Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Animal Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Animal Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Animal Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Antidepressant Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Antidepressant Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Antidepressant Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Antipsychotic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Antipsychotic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Antipsychotic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Prion Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • JAPAN
    • Prion Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • CHINA
    • Prion Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: China 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • EUROPE
    • Prion Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Prion Disease Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Prion Disease Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for Prion Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • FRANCE
    • Prion Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: France Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: France 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • GERMANY
    • Prion Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Germany 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Italy 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Prion Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: UK 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 74: Spain Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Spain Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Spain 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 80: Russia Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Russia Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Russia 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Prion Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Prion Disease Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Prion Disease Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for Prion Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Prion Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 101: Australia Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Australia Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Australia 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • INDIA
    • Prion Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 107: India Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: India Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: India 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 110: India Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 113: South Korea Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: South Korea Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: South Korea 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 119: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Asia-Pacific Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Rest of Asia-Pacific 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Prion Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 125: Latin America Recent Past, Current & Future Analysis for Prion Disease Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 126: Latin America Historic Review for Prion Disease Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Latin America 16-Year Perspective for Prion Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 134: Argentina Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Argentina Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Argentina 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 140: Brazil Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Brazil Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Brazil 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 146: Mexico Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Mexico Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Mexico 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 152: Rest of Latin America Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Latin America Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Rest of Latin America 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Prion Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 158: Middle East Recent Past, Current & Future Analysis for Prion Disease Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 159: Middle East Historic Review for Prion Disease Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Middle East 16-Year Perspective for Prion Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 167: Iran Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Iran Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Iran 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 173: Israel Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Israel Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Israel 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 179: Saudi Arabia Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Saudi Arabia Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Saudi Arabia 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 185: UAE Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: UAE Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: UAE 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 191: Rest of Middle East Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Middle East Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Middle East 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030
  • AFRICA
    • Prion Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 197: Africa Recent Past, Current & Future Analysis for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Africa Historic Review for Prion Disease Treatment by Treatment - Human Treatment and Animal Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Africa 16-Year Perspective for Prion Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Human Treatment and Animal Treatment for the Years 2014, 2025 & 2030
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Prion Disease Treatment by Drug - Antidepressant Drugs and Antipsychotic Agents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Prion Disease Treatment by Drug - Percentage Breakdown of Value Sales for Antidepressant Drugs and Antipsychotic Agents for the Years 2014, 2025 & 2030

IV. COMPETITION